

## Active Protocol Studies - Summa Health System

KEY
<i>ACH: Akron City Hospital</i>
<i>SBH: Summa Barberton Hospital</i>
<i>RMH: Robinson Memorial Hospital</i>
<i>SWRH: Summa Western Reserve</i>

Contacts	Phone	Pager	Title
<i>Joyce Neading</i>	<i>330-375-4221</i>	<i>3265</i>	<i>Program Director</i>
<i>Lynn Kaplan</i>	<i>330-375-6121</i>	<i>1642</i>	<i>Clinical Research Coordinator</i>
<i>Ann Stone</i>	<i>330-375-6578</i>	<i>1886</i>	<i>Clinical Research Nurse</i>
<i>Sarah Stanaszek</i>	<i>330-375-6390</i>	<i>3339</i>	<i>Clinical Research Nurse</i>

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Suspended	Title	Eligibility Requirements
<b>All Cancers</b>												
<i>All Cancers</i>	Merck V212 Open only to Solid Tumor Malignancy (no Hematologic malignancy)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy	Solid tumor or hematologic malignancy;no hematopoietic cell transplant (HCT); ≥ age 18 & tx does not include rituximab OR ≥age 50 not in remission & not receiving rituximab 3 months prior to enrollment through 28 days after dose 4. Life expect. 12 mos
<b>BRAIN</b>												
<i>Anaplastic glioma</i>	RTOG 0834 Alliance needs credentialing	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial	No prior chemo and no prior radiotherapy to the brain; PS 0-2; prior surgery for a low grade tumor is allowed, provided histological; Start of radiotherapy within 8 days from randomization; start of radiotherapy within 7 weeks (49 days) from surgery
<i>Brain Mets from Breast Cancer</i>	RTOG 1119	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG	Invasive breast cancer; HER2+; ≥ 1 measurable, new or progressive after SRS or surgical resection (1-3 mets);Karnofsky ≥60;No Prior WBRT;No Prior lapatinib tx;No Leptomeningeal dz
<i>Glioblastoma or Gliosarcoma - Recurrent</i>	RTOG 1122 Suspended	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/> Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma	Glioblastoma, gliosarcoma, glioblastoma w/ oligodendroglial features, giant cell glioblastoma; Karnofsky≥70; Chemo >28 days; RT>90 days;No surgical procedure < 28 days; No prior tx with anti-VEGF; < 2 relapses
<i>Glioblastoma</i>	RTOG 0913 Temp. Closed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/> Phase I/II Trial of Concurrent RAD001 (Everolimus) with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma	GBM (WHO Grade IV);Gliosarcoma OK; No recurrent/malignant glioma;No mets; Karnofsky 70-100; No prior temozolomide, mTOR inhibitor, Gliadel wafers or other intratumoral or intracavitary tx; No prior RT, radiosensitizers or chemo to the head, neck or brain
<i>Glioblastoma (recurrent)</i>	RTOG 0929 Suspended	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/> A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma (Now recruiting for Phase II)	Intracranial glioblastoma or gliosarcoma for the phase II component;evidence of tumor progression ≤ past 14 days; Completed a course of RT; Pts in phase II must also have completed ≥ 2 courses of temozolomide; Karnofsky ≥70; no hx of seizures

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<b>Low Grade Gliomas</b>	ECOG E3F05	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas	Grade 2 astrocytoma, oligodendroglioma or oligoastrocytoma; ≥1 of the following: uncontrolled headaches, seizures, focal neurological symptoms or Cognitive symptoms or deficits OR new or progressive enhancement; > 2wks brain surgery; no prior tx; PS ≥60
<b>Resected Brain Mets</b>	N107C (RTOG credit) ACH Only	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Trial of Post-Surgical Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease	≤ 4 brain mets; at least 1 lesion resected; non-CNS primary site; unresected lesions ≤ 3.0 cm, PS 0-2; no prior cranial RT; no planned chemo; no germ cell, small cell or lymphoma
<b>WBRT &amp; Stereotactic for 1-3 mets</b>	N0574 (RTOG credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With 1-3 Brain Metastases	1-3 brain mets, maximum tumor dimension <= 3 cm. per lesion, PS 0-2; no prior RT; no chemo during trt; ineligible primaries: germ cell, small cell, lymphoma
<b>WBRT for mets</b>	RTOG 0933 (ACH/Dr. Seider only)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases--RTOG CCOP Study	Brain mets (no SCLC & germ cell) ≤ 5 yrs of reg; NSCLC < 2 extracranial sites; unknown primary OK; meas brain mets outside 5-mm margin around either hippocampus ≤ 30 days reg; no SRS or surgery unless relapse; PS ≥ 70; no prior RT to brain; RPA Class I or II
<b>BREAST</b>												
<b>DCIS</b>	B-43	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy	HER2+, No pN1, must submit tumor block for central review prior to randomization. DO NOT ORDER HER-2 STUDIES (Done centrally)
<b>Early Stage</b>	RTOG 1005	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer	Stage I or II + 1 more requirement (see protocol) OR Stage 0 with grade 3 DCIS OR Stage 0, I, II resected by lumpectomy after neoadj systemic tx; No mets; No prior breast ca; No T4, N2 or N3, or M1; no prior RT; PS 0-2
<b>HER2 Neg Node + or High Risk Node -</b>	B-49	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Clinical Trial Comparing the Combination of Docetaxel plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer	HER2-, unilateral invasive adenoca, pT1-3; pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b; If pN0, must be: ER- & PgR- OR > 2.0 cm OR T1c and ER+ and either grade 3 OR Oncotype DX ≥ 25; rand ≤ 84 days; no T4 or inflammatory; no mets; PS 0-1; central rev tissue
<b>HER2 neg; Node +; ER+ and/or PR+;</b>	SWOG S1007 (NSABP credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less	1-3 node+; ER+ and/or PR+; HER2 neg; Recurrence Score (RS) by Oncotype DX® ≤ 25; Prior DCIS OK only if treated with mastectomy alone; No metastatic dz; PS 0-2; No prior chemo or endocrine tx

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Wooster</i>	<i>Salem</i>	<i>Alliance</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>HER2-Positive</i>	APHINITY: BIG 4-11	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy + Trastuzumab + Placebo Versus Chemotherapy + Trastuzumab + Pertuzumab As Adjuvant Therapy In Patients With Operable HER2-Positive Primary Breast	HER2+, >18 years old, PS 0-1, p T any, N any or for N0 dz must have tumor size > 1.0 cm OR > 0.5 cm and < 1.0 cm. must have one of the following nuclear grade 3 OR ER-, PR- or age < 35 (FEC/FAC-TH; AC-TH; TCH)
<i>HER2-Positive</i>	SCUSF 0806 (not endorsed yet)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®)	HER2-positive breast ca; Scheduled to receive adjuvant or neoadjuvant trastuzumab therapy; Hormone receptor and menopausal status not specified; No prior trastuzumab or anthracyclines; No known cardiac history
<i>Local Recurrence</i>	RTOG 1014	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBrI) for Local Recurrence of Breast Carcinoma	Locally recurrent breast cancer < 120 days; Tumor ≤ 3 cm; Initial lumpectomy followed by whole breast RT > 1year; whole-body PET-CT scan OR CT scan of the chest, abdomen, pelvis, & bone scan < 120 days; PS 0-1; No concurrent tx including trastuzumab
<i>Metastatic</i>	ECOG 2108	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Trial of the Value of Early Local Therapy (Surgery + RT after Chemo vs continued chemo only as needed for control of distant disease) for the Intact Primary Tumor in Patients with Metastatic Breast Cancer	Stage IV intact primary(not recurrent);prior DCIS OK if no recurrence;both M & F;no synch/contraltrl ca;≥1 distant met;CNS mets OK if LE >6 mos;had 16 wks chemo;no dz prog w/in 2 wks enrolling;candidates for complete resection w/ free margins following RT
<i>Node + or High Risk Node - HER2-Low</i>	B-47	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Trial Comparing Chemotherapy Alone to Chemotherapy + Trastuzumab in Women with Node+ or High-Risk Node- HER2-Low Invasive Breast Cancer	Adenoca; primary pT1-3, ipsilateral nodes pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b; No T4 tumors or inflammatory dz; no mets; no synchronous or previous contralateral invasive dz; HER2-low; PS 0-1; no prior tx;
<i>RT</i>	RTOG 0413 (NSABP B-39)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized, Phase III Study of Conventional Whole Breast Radiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer	Stage 0-II breast cancer, lumpectomy, tumor size ≤ 3.0 cm, ≤ 3 positive LNs (Ineligible: women ≥ age 50 with DCIS, or node negative & hormone receptor +)
<b>GI</b>												
<i>Bulky Tumor</i>	GRID	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Randomized Treatment of Advanced Bulky Malignancies with Spatially Fractionated Radiation Therapy	Cancer or sarcoma of H&N, lung abdomen or pelvis, bidimensional measured tumor >24 cm <sup>2</sup> , KPS>70, >3 month life expectancy
<i>Colon</i>	CALGB 80702 (NSABP Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer	Stage III completely resected; ≥ 1+ lymph node; no rectal ca; PS 0-2;No hx of upper GI ulceration, bleeding, or perforation ≤ 3 years; No concurrent NSAIDs > 2x wk or aspirin at > 325 mg ≥ 3 times per week;

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<i>Colon Prevention</i>	P-5	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Statin (Crestor) Polyp Prevention Trial in Patients with Resected Colon Cancer	Stage I or II adenocarcinoma of the colon w/ curative intent <1 year;complete resection;pre-op or post-op colonoscopy <180 days; >30 days since prior statins & prior investigational agents; no chronic use of NSAIDS (low dose aspirin OK);PS 0-1
<i>Colorectal</i>	ECOG 7208 Temporarily suspended	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy	Adenoca of the colon or rectum;adv dz,K-ras wild type;meas dz;had prior first-line therapy w/oxaliplatin-based fluoropyrimidine-containing chemo + bevacizumab; progression <42 days; no brain or CNS mets;PS 0-1;bevacizumab 28-90 days;surgery >28 days
<i>Colorectal (Older patients)</i>	N0949 ≥ age 70 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer	≥ age 70; metastatic colorectal cancer; no symptomatic or untreated CNS or brain mets; PS 0-2; Life Exp. ≥ 3 months; no prior tx for recurrent or met. colon ca; progressive dz > 12 mos of completing oxaliplatin
<i>Esophageal</i>	RTOG 1010	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma	Stage T1, N1-2 or T2-3, N0-2; No T1,N0 or T4 disease; No metastatic dz; able to have curative resection within 56 days after completion of chemoRT; No evidence of tracheoesophageal fistula or invasion into trachea or major bronchi; PS 0-2; No prior tx
<i>Esophageal or GE Junction</i>	ECOG 2208 Closing Oct. 15th	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer	Squamous cell or adenoca;local recurrence or local residual dz ; measurable dz post resection;either 1 prior systemic reg for met dz or 1 prior reg w/ RT for initial locally adv dz;PS 0-2 Life exp.≥12 weeks;surgery >4 weeks;No prior taxane or anti-EGFR tx
<i>Esophagus</i>	RTOG 0436 adenocarcinoma histology accrual closed	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery	Primary squamous cell of the esophagus (no adenocarcinoma), disease must be encompassed in a radiotherapy field, Stage T1N1M0; T2-4, Any N, M0; Any T, Any N, M1a, or gastroesophageal junction; no prior chemo; PS 0-2
<i>Esophagus</i>	S1201 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Pts Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	Unresectable adv or met adenoca of esophagus, stomach or GEJ; no prior tx for met dz;HER-2 neg; prior neo or adj tx ≥ 180 days;PS 0-1;no motor or sensory neuropathy;no plans for other concurrent tx; central review (Arm 1:FOLFOX; Arm 2:Taxotere+Irinotecan)
<i>GEJ</i>	S1201 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Pts Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	Unresectable adv or met adenoca of esophagus, stomach or GEJ; no prior tx for met dz;HER-2 neg; prior neo or adj tx ≥ 180 days;PS 0-1;no motor or sensory neuropathy;no plans for other concurrent tx; central review (Arm 1:FOLFOX; Arm 2:Taxotere+Irinotecan)
<i>Liver (Locally advanced or metastatic)</i>	CALGB 80802 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)	Locally adv or met HCC;meas dz; no CNS/brain mets;PS 0-2; No prior allografts; no prior VEGF; prior tx OK if >6 mo; no prior chemo for met dz; > 4 wks prior locoregional tx, interferon, surgery, or RT;

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<i>Pancreas</i>	RTOG 0848 (Alliance needs credentialing)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (Gemzar +/- Erlotinib; Step 2: +/- RT)	Resected pancreatic cancer, stage T1-3, N0-1, M0; No prior chemo; No prior total pancreatectomy, distal pancreatectomy, or central pancreatectomy; No prior RT to the region that would result in overlap of RT fields; No recurrent pancreatic cancer; PS 0-1
<i>Pancreas-metastatic</i>	PGX-ODSH-2011-PC1 (T-Gen)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Nab-Paclitaxel (Abraxane®) With or Without ODSH (2-0, 3-0 desulfated heparin) in First Line Treatment of Metastatic Pancreatic Cancer	Metastatic adenocarcinoma of the pancreas, no islet cell tumors, measurable dz ; no prior rx for metastatic dz, PS 0-2; ages 18-80; normal CA19-9 levels now permitted as long as all other inclusion/exclusion criteria are met.
<i>Stomach</i>	S1201 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Pts Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	Unresectable adv or met adenoca of esophagus, stomach or GEJ; no prior tx for met dz;HER-2 neg; prior neo or adj tx ≥ 180 days;PS 0-1;no motor or sensory neuropathy;no plans for other concurrent tx; central review (Arm 1:FOLFOX; Arm 2:Taxotere+Irinotecan)
<b>GU</b>												
<i>Bladder</i>	RTOG 0524	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer	Transitional cell ca, T2-4a, Nx-1, M0 OR T1, grade 3/3, tissue must be sent for her2/neu analysis; thorough TURB required
<i>Bladder</i>	RTOG 0926 (Alliance needs credentialing)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Re-Staging	T1G2 or T1G3 transitional cell ca that has recurred < 18 months after initial treatment for ≤ T1 tumors; T1, NX or N0, M0 without hydronephrosis; No pN+ or > T1 disease; no mets; PS 0-1; no prior chemo or RT
<i>Bulky Tumor</i>	GRID	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Randomized Treatment of Advanced Bulky Malignancies with Spatially Fractionated Radiation Therapy	Cancer or sarcoma of H&N, lung abdomen or pelvis, bidimensional measured tumor >24 cm2 , KPS>70, >3 month life expectancy
<i>Renal</i>	SWOG S0931 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	EVEREST: EVERolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (Everolimus vs Placebo X 54 weeks)	Renal cell ca; full resection (radical or partial nephrectomy); neg margins; bilateral renal tumors OK; no residual or metastatic dz; no prior tx; Zubrod PS 0-1
<i>Renal Advanced disease</i>	CALGB 90802 (not endorsed yet)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors	Clear cell, metastatic or unresectable; meas. dz; treated w/ ≥1 prior VEGFR tyrosine kinase inhibitor & progressed or tx intolerance; no active brain mets;PS 0-2;prior cytokines OK

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<b>Renal Advanced Sarcomatoid</b>	ECOG 1808	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features	Renal cell carcinoma with sarcomatoid features; meas dz not resectable; treated brain mets OK if off steroids .≥2 weeks; No prior systemic therapy for metastatic dz; > 2 wks RT; PS 0-2
<b>Renal Metastatic</b>	ECOG 4805 Re-opened to Arm A only	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma	Unresectable or met. renal cell ca;clear cell;meas.dz;failed a TKI;prior immunotx cytokine w/ interleukin2 & interferon alpha only;no prior chemo, cellular, vaccine or hormonal tx;prior RT OK if meas dz outside RT port ;PS 0-2; no CNS mets; RT ≥ 3 wks
<b>GYN</b>												
<b>Bulky Tumor</b>	GRID	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Randomized Treatment of Advanced Bulky Malignancies with Spatially Fractionated Radiation Therapy	Cancer or sarcoma of H&N, lung abdomen or pelvis, bidimensional measured tumor >24 cm2 , KPS>70, >3 month life expectancy
<b>Cervix</b>	GOG 0263	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy	Squamous cell,adenosquamous,adenocarcinoma; Stage I-IIA;radical hysterectomy & pelvic lymphadenectomy;no tumor in the parametria, pelvic lymph nodes, or other extra-uterine site; PS 0-2; surgery 3-8 weeks;no prior RT or chemo;
<b>Cervix</b>	GOG 0274 RTOG 1174	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial	FIGO 2008 Stage IB1 node+, IB2, II, IIIB or IVA; no prior chemo or pelvic RT; no Stage IIIA; no mets; no prior or planned hysterectomy;no interstitial brachy tx permitted; no IMRT and Rapid Arc permitted; PS 0-2
<b>Cervix</b>	RTOG 0724	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy	Stage IA2, IB, or IIA disease; Must have had radical hysterectomy; No neuroendocrine histology;No distant mets; PS 0-1;No prior chemo for the current cervical cancer; No prior RT to pelvis that would result in overlap of RT fields
<b>Cervix Recurrent</b>	GOG 0227-G Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/> A Phase II Evaluation of Brivanib (BMS582664, IND #108417) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)	Persistent or recurrent cervical cancer; meas dz; not eligible for a higher priority GOG protocol; 1 or 2 prior systemic chemo regimen; no brain mets; PS 0-2; prior RT OK
<b>Endometrial</b>	GOG 0249	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	Stage I high-intermed risk (grade 2 or 3, LV space invasion, and/or myometrial invasion);Stage II w/or w/out risk factors;Stage I-II dz w/ serous or clear cell w/or w/out other risk factors provided dz uterine-confined; no mets;total hyst 4-12 wks;PS 0-2

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<i>Endometrial</i>	GOG 0258	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Stage III or IVA endometrial ca per FIGO 2009; PS 0-2; no recurrent endometrial ca;no carcinosarcoma; no prior pelvic or abdominal RT;no prior chemo for endometrial ca; no residual > 2cm (FIGO 2009 Stage I or II clear cell or serous with + pelvic washings
<i>Endometrial - Recurrent</i>	GOG 0229-K	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Evaluation of BIBF 1120 (IND# 113086) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Recurrent or persistent endometrial ca, refractory to tx;meas dz; must have 1 target lesion; not eligible for higher priority protocol; must have had 1 prior chemo tx; no prior non-cytotoxic tx; no brain mets
<i>Leiomyosarcoma</i>	GOG 0131-H	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus	Persistent or recurrent dz refractory to tx; meas. dz.;Not eligible for a higher priority GOG protocol; Must have had 1 prior regimen that included a taxane; no brain mets; PS 0-2; >1wk hormonal tx; >3 wks prior tx; >4 wks RT
<i>Leiomyosarcoma</i>	GOG 0250	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF With Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus	Advanced or recurrent uterine leiomyosarcoma; meas. dz; > 1 target lesion; no CNS; PS 0-2; >1 wk hormonal tx; no prior cytotoxic chemo, VEGF, multi-kinase inhibitors; no prior docetaxel or gemcitabine; > 28 days major surgery; > 7 days minor surgery
<i>Leiomyosarcoma</i>	GOG 0277	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) versus Observation for Uterus-limited, High Grade Uterine Leiomyosarcoma	High risk uterine LMS, FIGO stage I; had complete hysterectomy; no mets; PS 0-1; no prior chemo with docetaxel, gemcitabine or doxorubicin ever; no prior whole pelvic RT; no recurrent LMS; no HIV
<i>Lymphedema Study</i>	GOG 0244 (LEG STUDY - some training required)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> The Lymphedema and Gynecologic Cancer (LEG) Study: Incidence, Risk Factors and Impact in Newly Diagnosed Patients	Pts undergoing hyst/BSO & pelvic lymphadenectomy (Stage I-II uterine) OR radical hyst or trachelectomy & pelvic (Stage IA-IIA cervical) OR Stage I-IV vulvar cancer having vulvectomy or radical local excision w/ lymphadenectomy; PS 0-2
<i>Ovarian</i>	DUKE 1810	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Epidemiology of Ovarian Cancer in African American Women	African-American women with newly diagnosed invasive epithelial ovarian, fallopian tube or peritoneum cancer
<i>Ovarian</i>	GOG 0261	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Trial of Paclitaxel + Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary	Uterine or ovarian carcinosarcoma w/≥ 1 of these:newly diagnosed dz,Stage I-IV,recurrent or chemo-naïve;PS 0-2;No prior chemo for uterine or ovarian ca;RT > 4 wks;hormonal tx > 1 wk;No planned RT after or during study tx;may be unstaged;meas or non-meas dz
<i>Ovarian</i>	GOG 0268	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Evaluation of Temsirolimus (CCI-779) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary	Newly diagnosed stage III or IV clear cell ovarian ca;PS 0-2;Neuro function ≤ grade 1;No severely impaired lung function;No prior tx with a mTOR inhibitor, paclitaxel, or carbo;No prior RT or chemo to any portion of the abdomen or pelvis;surgery 2-12 wks

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
Ovarian	TLC177.2 TEVA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Open-Label Crossover Study of Bioequivalence and Safety of Doxorubicin Hydrochloride Liposome Injection Formulations in Patients with Advanced Carcinoma of the Ovary	Ovarian cancer which has progressed or recurred after platinum-based chemo; Age 20-75; PS 0-2; no prior RT to mediastinum or more than 1/3 hematopoietic sites; >30 days prior to Day 1 of chemo, hormonal or biological agents; agrees to PK sampling
Ovarian or Fallopian Tube	GOG 0241	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Trial of Open Label Carboplatin and Paclitaxel +/- Bevacizumab Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian Cancer or Fallopian Tube Cancer (MEOC)	Mucinous ca of ovary or fallopian tube; FIGO stage II-IV or recurrent stage I; No primary peritoneal ca; No brain mets; PS 0-2; Life expect >3 months; No prior chemo, RT or mouse antibody; surgery >4 weeks & none planned during study treatment; no warfarin
Ovarian, Fallopian Tube and Primary Peritoneal	GOG 0186-I	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase II Evaluation of Single-Agent Bevacizumab and Combination Bevacizumab with Fosbretabulin Tromethamine (CA4P) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal	Platinum-sensitive recurrent disease. Measurable or detectable dz; 1 prior platinum initial trt; up to 2 trt for recurrent/persistent dz; not eligible for a higher priority GOG protocol; PS 0-2 for 1 prior tx; PS 0-1 for 2+ tx;
Ovarian, Fallopian Tube and Primary Peritoneal	GOG 0212	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Trial of Paclitaxel or Polyglutamate Paclitaxel (CT-2103) or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer	Primary peritoneal or Stage III or IV epithelial ovarian or fallopian tube ca with either optimal ≤ 1 cm residual dz or suboptimal residual dz after initial surgery; had 5-8 cycles tx ≤ 12 wks; no sx of persistent ca, normal CT scan & CA-125; PS 0-2
Ovarian, Fallopian Tube and Primary Peritoneal	GOG 0260 Suspended effective 4.5.12	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Meas dz; must have had 1 prior platinum-based chemo tx; must be platinum-resistant or refractory; not elig. for higher GOG protocol; PS 0-2; >1 wk prior hormonal tx; >3 wks prior biological or immunotherapy; see RT tx rule
Ovarian, Fallopian Tube and Primary Peritoneal	GOG 0267 QOL STUDY	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian tube, and Peritoneal Cancer	Recurrent or persistent ovarian, peritoneal or fallopian tube platinum-resistant cancer (< 6 months from date of last platinum tx to recurrence); life expectancy > 6 months; any PS but must be able to verbally consent and participate in the first assessment
Ovarian, Fallopian Tube and Primary Peritoneal	GOG 0280 Temp. Closed	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Phase II Evaluation of PARP -1 and -2 Inhibitor Veliparib (ABT-888) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients who Carry a Germline BRCA 1 or BRCA2 Mutation	Recurrent or persistent dz AND have BRCA1 or 2; must have meas. dz; if 1 prior tx then PS 0-2, if 2 or 3 prior tx then PS 0-1. RT ≥4wks; must have 1 prior platinum-based tx (up to 3 total); platinum refract not eligible; no prior PARP inhibitor; no seizures
Ovarian, Fallopian Tube and Primary Peritoneal	GOG 0273 ≥ age 70	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> GOG 0273 Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer	≥ age 70; Adenoca of ovary, peritoneum or fallopian tube; FIGO I, II, III & IV; no prior tx except for surgery; register ≤ 8 weeks confirmation of dx or 12 wks of primary/staging surgery; PS 0-3; phys choice primary surgery vs chemo + 2 chemo regimen choices
Ovarian, fallopian tube or primary peritoneal cancer	GOG 0259 QOL STUDY	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Nurse-Delivered Write Symptoms© vs. Self-Directed Write Symptoms© vs. Care As Usual For Optimal Symptom Management For Women With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Ovarian, fallopian tube, or primary peritoneal cancer that has recurred or persisted following primary therapy; must be experiencing ≥ 3 symptoms associated with ovarian cancer or cancer tx; PS 0-2; read and write English; Access to computer & the Internet

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<i>Ovarian, Fallopian tube, or Peritoneal Cavity Cancer</i>	GOG 0213	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Randomized Controlled Clinical Trial of Carboplatin & Paclitaxel Alone or In Combination with Bevacizumab Followed By Bevacizumab & Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Peritoneal & Fallopian Tube	Recurrent, meas. disease; dz-free=6 mo; MUST BE CANDIDATES FOR CYTOREDUCTIVE SURGERY AND CONSENT TO HAVE THEIR SURGICAL TREATMENT DETERMINED BY RANDOMIZATION; PS 0-2; only 1 prior chemo tx; no prior RT; no CNS;No concurrent
<i>Uterine</i>	GOG 0261	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase III Trial of Paclitaxel + Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary	Uterine or ovarian carcinosarcoma w/≥ 1 of these:newly diagnosed dz,Stage I-IV,recurrent or chemo-naïve;PS 0-2;No prior chemo for uterine or ovarian ca;RT > 4 wks;hormonal tx > 1 wk;No planned RT after or during study tx;may be unstaged;meas or non-meas dz
<i>Uterine carcinosarcoma</i>	GOG 0130-F	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Recurrent or progressive uterine carcinosarcoma; meas dz; > 3 wks prior tx; >1 wk prior hormonal tx; PS 0-2; not eligible for higher priority GOG protocol; prior tx with Taxane required
<i>Uterine Recurrence</i>	GOG 0238	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Biopsy proven recurrent endometrial ca confined to the pelvis and/or vagina;No evidence of extra pelvic dz;PS 0-2;Prior primary surgical debulking OK; no exenterative surgery;>6 mo prior hormone or chemo tx; no prior RT;no neoadj.chemo for recurrent dz
<b>HEAD &amp; NECK</b>												
<i>Advanced (includes thyroid)</i>	RTOG 0920	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer	Squamous cell T1, N1-2 or T2-4a, N0-2, M0; no + margins;no prior chemo,anti-EGF or RT;PS 0-1;≥ 1 risk factor: perineural or lymph. invasion,1 node >3cm or ≥2+ nodes <6cm,close margin(s),T3 or T4a primary,T2 oral ca >5mm depth;T1-2, N0, M0 resected thyroid
<i>Bulky Tumor</i>	GRID	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Randomized Treatment of Advanced Bulky Malignancies with Spatially Fractionated Radiation Therapy	Cancer or sarcoma of H&N, lung abdomen or pelvis, bidimensional measured tumor >24 cm <sup>2</sup> , KPS>70, >3 month life expectancy
<i>Oropharynx</i>	RTOG 1016	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer (HPV+)	Squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate or oropharyngeal walls) stage T1-2, N2a-3, or T3-4 any N; TUMOR MUST BE p16 POSITIVE. No mets; measurable dz; PS 0-1;No prior tx; Central path for review to confirm
<i>Recurrent/ Metastatic</i>	ECOG 1305	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer	Recurrent or metastatic SCCHN; no prior tx for recurrence/mets;no prior bevacizumab; prev. palliative RT OK if > 8 wks; surgery > 4 wks; no brain mets; no lung mets;no bleeding disorders; no chronic daily aspirin, PS 0-1

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<i>Salivary Gland Tumors</i>	RTOG 1008	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors	Stage T3-4 or N1-3 or T1-2, N0 with a positive margin; high-grade mucoepidermoid carcinoma, high-grade adenocarcinoma, or salivary duct carcinoma; Surgical resection <8 wks; no mets; PS 0-1; No prior chemo or RT for salivary gland cancer
<i>Thyroid</i>	RTOG 0912	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel, and Pazopanib (NSC 737754)/Placebo for the Treatment of Anaplastic Thyroid Cancer	Anaplastic thyroid cancer;No brain mets;PS 0-2; No prior chemo for anaplastic thyroid cancer; No chemo or RT < 4 weeks of registration; No other investigational agents; No prior RT that would result in overlap of RT fields; No pts who require heparin
<b>LEUKEMIA</b>												
<i>AML (Older Adults)</i>	ECOG 2906 NOTE: Daunorubicin Shortage check with Pharmacy before enrolling	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Randomized Trial of Clofarabine as Induction & Post-Remission Tx vs Standard Daunorubicin & Cytarabine Induction & Intermediate Dose Cytarabine Post-Remission Tx, Followed by Decitabine Maint vs Observation in Newly-Diag AML in Adults ≥ 60	≥ 60 Years;newly diag AML;no AML-M3 or t (15;17)(q22;q21);no blastic trans of CML;no CNS; Must also enroll on ECOG 3903;PS 0-3;no prior tx with azacitidine, decitabine or low-dose cytarabaine for MDS;prior hydroxyurea OK;bone marrow aspirate req to enroll
<i>CLL</i>	Connect CLL Registry	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Connect CLL: The Chronic Lymphocytic Leukemia Disease Registry	New diagnosis within 2 months of enrollment; >= age 18; able to read & speak English; agrees to complete all questionnaires; cannot participate in a treatment clinical study in which study treatment is blinded; life expectancy > 6 months
<i>Lab Study (to determine eligibility-mandatory with</i>	ECOG 3903	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders	Must be planing to enroll in an ECOG leukemia treatment clinical trial
<i>PNH</i>	PNH Registry	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Paroxysmal Nocturnal Hemoglobinuria (PNH) Subject Registry	Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) or a detected PNH clone. May or may not be receiving Soliris; also including patients previously treated with Soliris who have withdrawn from treatment.
<b>LUNG</b>												
<i>Bulky Tumor</i>	GRID	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Randomized Treatment of Advanced Bulky Malignancies with Spatially Fractionated Radiation Therapy	Cancer or sarcoma of H&N, lung abdomen or pelvis, bidimensional measured tumor >24 cm <sup>2</sup> , KPS>70, >3 month life expectancy
<i>Mesothelioma</i>	CALGB 30901 (ECOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Randomized Phase II Study of Maintenance Pemetrexed Versus Observation For Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy	Completed 4 cycles of 1st line chemo w/ pemetrexed AND either cisplatin or carbo with CR, PR or stable dz; prior surgery and/or RT OK

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
NSCLC	Amgen Anemia 20070782	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety & Efficacy of Darbepoetin Alfa Administered at 500 ug Once- Every-3-Weeks in Anemic Subjects With Advanced Stage NSCLC Receiving Multi-cycle Chemotherapy	Stage IV NSCLC; must be receiving 2 cycles of 1st line chemo; PS 0-1 < 21 days randomization; Life Exp. > 6 mo; Hemoglobin ≤ 11.0 w/in 7 days rand; no prior adj or neoadj tx for NSCLC; no brain mets; no RBC transfusion or ESAs < 28 days;
NSCLC	RTOG 0813	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable Patients	NSCLC, Stage T1-2, N0, M0; Tumor resectable; patient "medically inoperable"; Measurable dz < 8 weeks; PS 0-2; No prior RT that would result in overlap of RT fields; No prior chemo; No other concurrent local therapy or systemic therapy
NSCLC	RTOG 0839	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer	Stage IIIA (T1-T3) (N1 or N2) meas dz; no palpable LN in the supraclavicular areas or higher unless benign by bx; no mets; PS 0-1; No prior chemo, biological tx or RT
NSCLC <i>(need 2 cycles paclitaxel on hand to enroll)</i>	ECOG 3508	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer	Stage IV or recurrent non-squamous NSCLC; meas dz; treated brain mets OK; no prior tx for advanced dz; > 1 year prior tx; > 3 wks RT; > 4wks surgery; no concurrent cancer tx or anticoagulation tx; no HIV+ pts; no uncontrolled diabetes; PS 0-1;
NSCLC <i>Protocol Notice: Shortage of Paclitaxel</i>	ECOG 1505	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB (>= 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)	Completely resected, Stage IB (> 4 cm) – IIIA (T2-3N0, T1-3N1, T1-3N2 per AJCC 6th ed.); proper lymph node level resection; 6-12 weeks post surgery; PS 0-1; no prior chemo (Cisplat w/ Vinorelbine/Alimta/Gemzar-MD choice)
SCLC	CALGB 30610 (RTOG Credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide	Limited stage SCLC; must have measurable dz; no contralateral hilar or supraclav lymph nodes; no prior chemo or RT; no prior mediastinal or thoracic RT; no complete surgical resection; PS 0-2
SCLC <i>(prophylactic Cranial RT for extensive disease)</i>	RTOG 0937	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)	Extensive stage SCLC ≤ 6 months; 1-3 extracranial mets; completed 4-6 courses of platinum-based chemo ≤ 8 wks AND one of the following: partial or complete response in ≥ 1 site of dz OR No progression in any site; PS 0-2; No brain or CNS mets;
<b>LYMPHOMA</b>												
B CELL	C05013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma	Pts previously untreated DLBCL subclassified as non-GCB subtype; least 1 measurable tumor mass that is > than 1.5 cm in the long axis and > than 1.0 cm in the short axis; No CNS lymphoma

<i>Site</i>	<i>Protocol #</i>	<i>ACH</i>	<i>SBH</i>	<i>SWRH</i>	<i>RMH</i>	<i>Medina</i>	<i>Wooster</i>	<i>Salem</i>	<i>Alliance</i>	<i>Sus-pended</i>	<i>Title</i>	<i>Eligibility Requirements</i>
<i>CNS</i>	ECOG E1F05 Temporarily suspended	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	(Suspended for toxicity analysis) Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma	Primary CNS Non-Hodgkin's lymphoma; no prior chemo or RT for CNS; pre-treatment steroid administration OK; meas dz; HIV-1 neg; HepB neg; PS 0-3
<i>Follicular</i>	ECOG 2408	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma	Stage II, III, or IV AND grade 1, 2, or 3a; must have FLIPI-1 score of 3, 4, or 5 (1 point per criterion); Age ≥ 60, Stage III-IV, Hemoglobin level <12 g/dL, >4 nodal areas, Serum LDH level above normal; Meas dz; PS 0-2; No prior chemo, RT, or immunotherapy
<i>Hodgkin's</i>	SWOG S0816 (ECOG credit)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging	Classical Hodgkin lymphoma previously untreated Stage III or IV; Bidimensionally measurable dz; bone marrow biopsy < 42 days; PS 0-2; Age 18-60
<i>Mantle Cell</i>	ECOG 1411	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Intergroup Randomized Phase II Four Arm Study In Patients ≥/≤ Age 60 with Previously Untreated Mantle Cell Lymphoma of Therapy with Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide	Age 60+; untreated mantle cell; meas dz; PS 0-2; no CNS; meas. dz; HIV+ OK (must meet criteria)
<b>MELANOMA</b>												
<i>Mucosal, Acral, &amp; Solar</i>	ECOG 2607	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas	Metastatic or unresectable melanoma (acral, vagina and/or vulva, or other mucosal surface); meas. dz; must be KIT+; prior trt. OK, but NO targeted tx permitted; prior trt. > 4 weeks; CNS OK if treated and stable; PS 0-1 **Mandatory central review-tissue
<i>Resected, high-risk</i>	ECOG 1609	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon α-2b for Resected High-Risk Melanoma	Stage IIIB, IIIC, or IV (M1a or M1b); No ocular or mucosal melanoma; completely resected w/ neg margins <12 wks; Dz recurrence OK but see protocol; No prior adjuvant treatment after resection; >30 days RT; > 4wks IL-2 or other chemo; PS 0-1
<b>PREVENTION</b>												
<i>Colon</i>	P-5	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Statin Polyp Prevention Trial in Patients with Resected Colon Cancer	Stage I or II adenocarcinoma of the colon w/ curative intent <1 year; complete resection; pre-op or post-op colonoscopy <180 days; >30 days since prior statins & prior investigational agents; no chronic use of NSAIDS (low dose aspirin OK); PS 0-1
<b>PROSTATE</b>												
<i>3D/IMRT</i>	RTOG 0534	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy	T3N0/Nx or T2N0/Nx with + or - margin; PSA DOUBLING TIME > 6 MONTHS PRIOR TO REG.; no hormones prior to reg; Zubrod 0-1, no mets; NO TIME LIMIT FROM PROSTATECTOMY; No CNCMO, No RT; prostate Gleason ≤ 9, PSA ≥0.1 - <2.0

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<b>3D/IMRT</b>	RTOG 0815	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer	Adenoca of the prostate diagnosed < 6 months; Gleason 7 or PSA > 10 but ≤ 20 ng/mL or stage T2b or T2c; Clinically negative lymph nodes; No evidence of bone mets; PS 0-1; no prior radical surgery, hormonal therapy, chemo or RT; No finasteride ≤/ = 30 days
<b>Favorable Risk</b>	RTOG 0938 IGRT Credentialing Pending	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer	Adenoca of the prostate; T1-2a; Gleason 2-6; PSA < 10; PS 0-1; no prior or concurrent invasive dz; no mets; no LN involved; no prior pelvic surgery, chemo, RT or hormones; ≥ 30 days after finasteride use; ≥ 90 days after dutasteride use
<b>Intermediate or Favorable High Risk</b>	RTOG 0924 (Alliance needs brachy, IMRT credentialing)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial	Dx'd within past 180 days, GS 7-10 + T1c-T2b + PSA <50; GS 6 + T2c-T4 or >50% positive biopsies + PSA <50; GS 6 + T1c-T2b + PSA >20; no mets; no previous tx ; PS 0-1
<b>Local Recurrence</b>	RTOG 0526 (Salem needs Prostate Brachy credentialing)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy	Bx documented locally recurrent prostate adeno >30 months after EBRT and ≤ 180 days prior to reg; initial diagnosis T1-T2c, GS 2-6, PSA ≤20; OR T1-T2c, GS 7, PSA ≤10; N0; hormonal tx OK; no mets; PS 0-1; PSA<10
<b>Metastatic disease</b>	ECOG 3805	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	CHAARTED: ChemoHormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (Docetaxel Provided)	Met dz (both low volume & high volume dz) High volume is visceral mets; if no visceral lesions, must be ≥ 4 bone lesions, 1 of which is outside spine/pelvis; hormones for ≤ 120 days; PS 0-2; prior palliative RT OK
<b>Non-Metastatic Prostate Cancer</b>	RTOG 0622	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Trial of Samarium 153 Followed By Salvage Prostatic Fossa 3C-CRT or IMRT Irradiation In High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy	Prostate ca, stage T2-T4, N0-N1; no distant mets; postop PSA 2.0; or postop PSA rising above 0.2 with a surgical tumor Gleason score of 9 or 10; or rapidly rising PSA profile with a doubling time < 6 months; no prior chemo; no hormones < 3 months; PS 0-1
<b>SARCOMA</b>												
<b>Leiomyosarcoma</b>	GOG 0131-H	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Phase II Evaluation of Ixabepilone (IND #59699, NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus	Persistent or recurrent dz refractory to tx; meas. dz.;Not eligible for a higher priority GOG protocol; Must have had 1 prior regimen that included a taxane; no brain mets; PS 0-2; >1wk hormonal tx; >3 wks prior tx; >4 wks RT
<b>Leiomyosarcoma</b>	GOG 0250	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF With Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus	Advanced or recurrent uterine leiomyosarcoma; meas. dz; > 1 target lesion; no CNS; PS 0-2; >1 wk hormonal tx; no prior cytotoxic chemo, VEGF, multi-kinase inhibitors; no prior docetaxel or gemcitabine; > 28 days major surgery; > 7 days minor surgery

Site	Protocol #	ACH	SBH	SWRH	RMH	Medina	Wooster	Salem	Alliance	Sus-pended	Title	Eligibility Requirements
<i>Leiomyosarcoma</i>	GOG 0277	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) versus Observation for Uterus-limited, High Grade Uterine Leiomyosarcoma	High risk uterine LMS, FIGO stage I; had complete hysterectomy; no mets; PS 0-1; no prior chemo with docetaxel, gemcitabine or doxorubicin ever; no prior whole pelvic RT; no recurrent LMS; no HIV
<i>Liposarcoma or Leiomyosarcoma</i>	ET743-SAR-3007	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide	Locally advanced or spreading liposarcoma or leiomyosarcoma that is unable to be removed by surgery; prior tx with an anthracycline & ifosfamide; Meas dz; PS 0-1; no prior tx with trabectedin or dacarbazine; > 3 weeks from prior tx; no CNS mets
<b>SPINE</b>												
<i>Metastatic</i>	RTOG 0631	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> (ACH ONLY) Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis	Localized spine metastasis from C1 to L5, a solitary spine metastasis; two sep. spine levels; or up to 3 separate site, Zubrod 0-2
<b>SUPPORTIVE CARE</b>												
<i>HER2-Positive</i>	SCUSF 0806 (not endorsed yet)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®)	HER2-positive breast ca; Scheduled to receive adjuvant or neoadjuvant trastuzumab therapy; Hormone receptor and menopausal status not specified; No prior trastuzumab or anthracyclines; No known cardiac history
<i>NSCLC</i>	Amgen Anemia 20070782	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety & Efficacy of Darbepoetin Alfa Administered at 500 ug Once- Every-3-Weeks in Anemic Subjects With Advanced Stage NSCLC Receiving Multi-cycle Chemotherapy	Stage IV NSCLC; must be receiving 2 cycles of 1st line chemo; PS 0-1 < 21 days randomization; Life Exp. > 6 mo; Hemoglobin ≤ 11.0 w/in 7 days rand; no prior adj or neoadj tx for NSCLC; no brain mets; no RBC transfusion or ESAs < 28 days;
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0267 QOL STUDY	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian tube, and Peritoneal Cancer	Recurrent or persistent ovarian, peritoneal or fallopian tube platinum-resistant cancer(< 6 months from date of last platinum tx to recurrence); life expectancy > 6 months; any PS but must be able to verbally consent and participate in the first assessment
<i>Ovarian, Fallopian Tube and Primary Peritoneal</i>	GOG 0273 ≥ age 70	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> GOG 0273 Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer	≥ age 70; Adenoca of ovary, peritoneum or fallopian tube; FIGO I, II, III & IV; no prior tx except for surgery; register ≤ 8 weeks confirmation of dx or 12 wks of primary/staging surgery; PS 0-3; phys choice primary surgery vs chemo + 2 chemo regimen choices
<i>Ovarian, fallopian tube or primary peritoneal cancer</i>	GOG 0259 QOL STUDY	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Nurse-Delivered Write Symptoms® vs. Self-Directed Write Symptoms® vs. Care As Usual For Optimal Symptom Management For Women With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Ovarian, fallopian tube, or primary peritoneal cancer that has recurred or persisted following primary therapy; must be experiencing ≥ 3 symptoms associated with ovarian cancer or cancer tx; PS 0-2; read and write English; Access to computer & the Internet